We bring
hope to life

People in dire medical need deserve
life-saving treatment.

Latest News

callout_nrx_latestupdates2x

NRx Pharmaceuticals and Quantum Leap Announce Treatment of Severely Ill COVID-19 Patients with ZYESAMI® (Aviptadil) in the I-SPY COVID Trial…

Latest News

callout_nrx_latestupdates2x

NRx Pharmaceuticals Announces Partnership with the Israel Institute for Biological Research to Complete Development and Commercialization of BriLife™ COVID Vaccine…

Pipeline

callout-pipeline2x

Research Pipeline

Our product candidates include compounds in Phase 2, and Phase 3 trials for COVID-19-related Lung Injury and Acute Respiratory Failure (ARDS) in partnership with Relief Therape…

ZYESAMI™ (Aviptadil)

callout-zyesami2x

ZYESAMI™

ZYESAMI™ (Aviptadil, previously RLF-100™), a synthetic form of human Vasoactive Intestinal Peptide (VIP) has been granted FDA Fast Track Designation for the investigational treatment of

NRX-100/NRX-101

callout-nrx-1002x

NRX-100/NRX-101

NRx’s investigational drug regimen NRX-100/NRX-101, if approved by the FDA, would be the first sequential medicine regimen to include an oral therapeutic to treat Bipolar Depression..

Bipolar Depression

callout-nrx-asib2x

Bipolar Depression in Patients with Acute Suicidal Ideation and Behavior (ASIB)In the United States, More than 100 People End Their Lives Each Day

Zyesami and NRX-100/NRX-101 are investigational therapies and have not been approved for human use by the Food and Drug Administration or European Medicines Agency.

Committed to
Life-Saving Treatments

NRx creates innovative, life-saving treatments to address unmet medical needs and bring hope to those with chronic conditions.

Learn More
NRx NRx